A recent review indicates that screening men for prostate cancer with a blood test could lower mortality rates related to the disease. The study, involving close to 800,000 patients, suggests that discussions about using the prostate-specific antigen (PSA) test for screening may be warranted. However, concerns persist regarding the risks of overdiagnosis and overtreatment, as highlighted by experts and Cancer Research UK.
Prostate cancer is the most common cancer in the UK, with over 64,000 new cases diagnosed annually. The debate over the effectiveness of the PSA test, which measures prostate-produced protein levels, continues. The test’s reliability has been questioned, as elevated PSA levels may not always indicate cancer, while normal levels could mask the presence of the disease.
One of the major issues with screening is the potential identification of non-threatening tumors, leading to unnecessary treatments and associated side effects like incontinence and erectile dysfunction. A recent Cochrane review examined data from six trials involving nearly 800,000 patients, showing a reduction in prostate cancer-related deaths with screening compared to no screening.
Despite these findings, concerns remain about the impact on quality of life, such as biopsy complications and sexual or urinary problems. The lead author stresses the imperfect nature of the PSA test and the varying types of prostate cancer, emphasizing the need for individualized decision-making between patients and their healthcare providers.
While the study supports discussions on PSA screening for men with suitable life expectancies, it does not universally endorse screening. The decision-making process should involve a thorough understanding of the potential benefits and risks associated with overdiagnosis and unnecessary treatment. Currently, the UK lacks a nationwide prostate cancer screening program, with screening recommended only for men with specific genetic mutations.
In light of the Cochrane review’s conclusions, it is evident that the current screening methods may not be sufficiently effective. Balancing the benefits and risks of screening remains a complex challenge. Ongoing research, such as the Transform trial, aims to explore new screening approaches, including genetic tests and MRI scans, to improve the accuracy and efficiency of prostate cancer screening methods.